Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) Operating Expenses (2017 - 2025)

Dianthus Therapeutics (DNTH) has 7 years of Operating Expenses data on record, last reported at $40.7 million in Q3 2025.

  • For Q3 2025, Operating Expenses rose 26.85% year-over-year to $40.7 million; the TTM value through Sep 2025 reached $143.4 million, up 62.44%, while the annual FY2024 figure was $108.1 million, 111.96% up from the prior year.
  • Operating Expenses reached $40.7 million in Q3 2025 per DNTH's latest filing, up from $35.1 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $40.7 million in Q3 2025 and bottomed at -$2.2 million in Q3 2022.
  • Average Operating Expenses over 4 years is $21.4 million, with a median of $18.7 million recorded in 2024.
  • The widest YoY moves for Operating Expenses: up 853.86% in 2023, down 65.77% in 2023.
  • A 4-year view of Operating Expenses shows it stood at $11.9 million in 2022, then increased by 13.02% to $13.4 million in 2023, then soared by 147.83% to $33.2 million in 2024, then rose by 22.39% to $40.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $40.7 million in Q3 2025, $35.1 million in Q2 2025, and $34.3 million in Q1 2025.